OXGENE and Wuxi Advanced Therapies, the sponsor of this content would like to send you information about their products and services. If you do not wish to receive these emails, click here to opt out.
In this demo video, Dr Cawood explains what TESSA technology – a novel, plasmid free approach to AAV manufacture – is and how it works. He introduces what effect TESSA-based AAV manufacture has on AAV yield and quality and outlines the benefit he sees this delivering to patients.
“TESSA can significantly reduce the costs of manufacturing AAV. The number of input reagents is significantly lower, the efficiency with which they’re delivered to the cells is significantly higher, and the productivity of the system is significantly higher as well.”
Xavier De Mollerat Du Jeu, Senior Director R&D at Thermo Fisher Scientific is accompanied by Gianluca Pettiti, Executive Vice President and President, Life Sciences Group at Thermo Fisher Scientific and Fred Parietti, Co-Founder and CEO at Multiply Labs for this Workshop at Advanced Therapies Week 2024.
Manufacturing capacity, complexity and cost are core constraints that limit commercialization of cell and gene therapies, and ultimately patient access. In this Fireside Chat series, join Georgi Makin, VP of Digital & Editorial at Phacilitate and the Germfree team as we discuss the challenges and opportunities associated with delivering cell therapies in a decentralized manufacturing model.